Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ginsenoside Rg3 (Dalian Fusheng Pharmaceutical Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Dalian Fusheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ginsenoside Rg3 (brand name Shengtan) is a tetracyclic triterpenoid saponin monomer isolated from the roots of *Panax ginseng*. Developed by Dalian Fusheng Pharmaceutical, it was approved by the Chinese NMPA as a Class I new drug for the treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy. Its primary mechanism of action involves the inhibition of tumor angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), such as MMP-2 and MMP-9. Additionally, it exhibits immunomodulatory effects, enhancing the activity of natural killer (NK) cells and T lymphocytes, thereby improving the immune response and quality of life in cancer patients.
- Brand names
- ShengtanShengyi
- Other names
- Shengtan ginseng20(R)-ginsenoside Rg3Ginsenoside Rg3
02
Targets
MMP2 (Matrix metalloproteinase-2)VEGFA (Vascular endothelial growth factor A)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on ginsenoside Rg3 (Dalian Fusheng Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ginsenoside Rg3 (Dalian Fusheng Pharmaceutical Co., Ltd.).